{"transactions":[{"id":3020537,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":146384,"kind":"person","name":"Nextech V Oncology S.C.S., SICAV-SIF","position":1,"cik":"0001712922","reported_name":"Nextech V Oncology S.C.S., SICAV-SIF","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":146385,"kind":"organization","name":"NEXTECH V GP S.A R.L.","position":2,"cik":"0001826326","reported_name":"NEXTECH V GP S.A R.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":146386,"kind":"person","name":"Bleyer Dalia","position":3,"cik":"0001826431","reported_name":"Bleyer Dalia","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":146387,"kind":"person","name":"Lips Thomas","position":4,"cik":"0001826413","reported_name":"Lips Thomas","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":146388,"kind":"person","name":"Detournay Philippe","position":5,"cik":"0001826386","reported_name":"Detournay Philippe","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series D Preferred Stock","published_at":"2020-09-29T20:49:41.000Z","date":"2020-09-29","kind":"exercise","acquired":false,"shares":760267,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. Thilo Schroeder is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. Mr. Schroeder is a director of the Issuer and files separate Section 16 reports. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV SIF. Dalia Bleyer, Philippe Detournay and Thomas Lips are Managers of Nextech V GP S.a r.l. and each of Nextech V GP S.a r.l., Ms. Bleyer and Messrs. Detournay and Lips may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership over such shares, except to the extent of his, her or its respective pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":760267},"source":{"system":"sec-edgar","filing":"0001209191-20-052353","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1699382/000120919120052353/doc4.xml","form_type":"4"}},{"id":3020536,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":146384,"kind":"person","name":"Nextech V Oncology S.C.S., SICAV-SIF","position":1,"cik":"0001712922","reported_name":"Nextech V Oncology S.C.S., SICAV-SIF","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":146385,"kind":"organization","name":"NEXTECH V GP S.A R.L.","position":2,"cik":"0001826326","reported_name":"NEXTECH V GP S.A R.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":146386,"kind":"person","name":"Bleyer Dalia","position":3,"cik":"0001826431","reported_name":"Bleyer Dalia","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":146387,"kind":"person","name":"Lips Thomas","position":4,"cik":"0001826413","reported_name":"Lips Thomas","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":146388,"kind":"person","name":"Detournay Philippe","position":5,"cik":"0001826386","reported_name":"Detournay Philippe","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series C Preferred Stock","published_at":"2020-09-29T20:49:41.000Z","date":"2020-09-29","kind":"exercise","acquired":false,"shares":1768023,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. Thilo Schroeder is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. Mr. Schroeder is a director of the Issuer and files separate Section 16 reports. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV SIF. Dalia Bleyer, Philippe Detournay and Thomas Lips are Managers of Nextech V GP S.a r.l. and each of Nextech V GP S.a r.l., Ms. Bleyer and Messrs. Detournay and Lips may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership over such shares, except to the extent of his, her or its respective pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1768023},"source":{"system":"sec-edgar","filing":"0001209191-20-052353","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1699382/000120919120052353/doc4.xml","form_type":"4"}},{"id":3020535,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":146384,"kind":"person","name":"Nextech V Oncology S.C.S., SICAV-SIF","position":1,"cik":"0001712922","reported_name":"Nextech V Oncology S.C.S., SICAV-SIF","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":146385,"kind":"organization","name":"NEXTECH V GP S.A R.L.","position":2,"cik":"0001826326","reported_name":"NEXTECH V GP S.A R.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":146386,"kind":"person","name":"Bleyer Dalia","position":3,"cik":"0001826431","reported_name":"Bleyer Dalia","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":146387,"kind":"person","name":"Lips Thomas","position":4,"cik":"0001826413","reported_name":"Lips Thomas","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":146388,"kind":"person","name":"Detournay Philippe","position":5,"cik":"0001826386","reported_name":"Detournay Philippe","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2020-09-29T20:49:41.000Z","date":"2020-09-29","kind":"exercise","acquired":true,"shares":760267,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. Thilo Schroeder is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. Mr. Schroeder is a director of the Issuer and files separate Section 16 reports. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV SIF. Dalia Bleyer, Philippe Detournay and Thomas Lips are Managers of Nextech V GP S.a r.l. and each of Nextech V GP S.a r.l., Ms. Bleyer and Messrs. Detournay and Lips may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership over such shares, except to the extent of his, her or its respective pecuniary interest therein, if any."}],"balance_after":2528290,"source":{"system":"sec-edgar","filing":"0001209191-20-052353","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1699382/000120919120052353/doc4.xml","form_type":"4"}},{"id":3020534,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":146384,"kind":"person","name":"Nextech V Oncology S.C.S., SICAV-SIF","position":1,"cik":"0001712922","reported_name":"Nextech V Oncology S.C.S., SICAV-SIF","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":146385,"kind":"organization","name":"NEXTECH V GP S.A R.L.","position":2,"cik":"0001826326","reported_name":"NEXTECH V GP S.A R.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":146386,"kind":"person","name":"Bleyer Dalia","position":3,"cik":"0001826431","reported_name":"Bleyer Dalia","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":146387,"kind":"person","name":"Lips Thomas","position":4,"cik":"0001826413","reported_name":"Lips Thomas","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":146388,"kind":"person","name":"Detournay Philippe","position":5,"cik":"0001826386","reported_name":"Detournay Philippe","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2020-09-29T20:49:41.000Z","date":"2020-09-29","kind":"exercise","acquired":true,"shares":1768023,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. Thilo Schroeder is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. Mr. Schroeder is a director of the Issuer and files separate Section 16 reports. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV SIF. Dalia Bleyer, Philippe Detournay and Thomas Lips are Managers of Nextech V GP S.a r.l. and each of Nextech V GP S.a r.l., Ms. Bleyer and Messrs. Detournay and Lips may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership over such shares, except to the extent of his, her or its respective pecuniary interest therein, if any."}],"balance_after":1768023,"source":{"system":"sec-edgar","filing":"0001209191-20-052353","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699382/000120919120052353/doc4.xml","form_type":"4"}}]}